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A RETROSPECTIVE COMPARISON OF THE IMPACT OF DARBEPOETIN
OR EPOETIN USAGE ON RED CELL TRANSFUSIONS TRANSFUSIONS IN
AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR LIGHT-CHAIN
RELATED AMYLOIDOSIS
Baribeault, D.M., Finn, K.T., Kunz, R., Seldin, D.C., Sanchorawala,
V. Boston Medical Center, Boston, MA
Background: In addition to providing cancer care, including
anemia management to an inner city population, Boston Medical
Center conducts approximately 50 stem cell transplantation (SCT)
procedures annually, primarily as treatment for light-chain related
Amyloidosis. In an attempt to limit the number of red blood cell
units transfused in the post-transplant period, erythropoeitic
growth factors (EGF) have become a standard addition to the
transplant protocol. As part of a much broader cost-savings plan,
the EGF of choice at Boston Medical Center was changed from
epoetin to darbepoetin in August 2002. Methods: Due to the
paucity of data in darbepoetin usage in the post-transplant setting,
a treatment dose of 200mcg weekly was arbitrarily chosen, loosely
based on FDA labeling. In an attempt to ensure that the change of
preferred agent would not negatively impact transfusion rates for
our SCT population, a retrospective review of two cohorts of
patients was conducted. The primary endpoint was number of
PRBC units transfused. Secondary endpoints included length of
erythropoeitic growth factor therapy; and drug acquisition costs.
Results: The number of patients, and the incidence of all grades of
GI bleeding in each cohort was equal. Baseline renal function for
the two groups was evenly matched. The mean number of PRBCs
transfused was 5.529 and 3.368, respectively, for the epoetin and
darbepoetin treatment cohorts (p  0.316). Length of therapy was
2.03 and 1.88 weeks, respectively, for the epoetin and darbepoetin
treatment cohorts (p  0.674). The average cost of therapy was
higher in the darbepoetin group with an average of $1200.00 vs.
$825.00. Conclusions: Although there was a trend toward de-
creased length of post-transplant treatment and number of PRBCs
transfused in the darbepoetin treatment cohort, there was no sig-
niﬁcant difference between darbepoetin and epoetin for all clinical
endpoints. Although there is an apparent cost difference between
the therapies, the overall ﬁnancial impact of darbepoetin usage at
our institution is positive. With emerging data on the usage of
lower than FDA indicated doses for chemotherapy-induced ane-
mia, it may be possible to use lower darbepoetin doses in the
post-transplant setting. Further study of darbepoetin in the pre and
post-SCT setting is warranted.
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ORAL CRYOTHERAPY FOR PREVENTION OF HIGH-DOSE MELPHALAN-
INDUCED STOMATITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS
Aisa, Y., Mori, T., Kudo, M., Yashima, T., Kondo, S., Ikeda, Y.,
Okamoto, S. Keio BMT Program, Keio University Hospital, Tokyo,
Japan
High-dose melphalan has been used in combination with total
body irradiation or other chemotherapeutic agents such as ﬂudara-
bine in myeloablative or nonmyeloablative allogeneic hematopoi-
etic stem cell transplantation. Moderate to severe oral mucositis is
a prominent feature of the toxicity of high-dose melphalan, which
interferes with nutrition and quality of life, and leads to the sec-
ondary infection. We have incorporated oral cryotherapy into the
reduced-intensity conditioning consisting of high-dose melphalan
for allogeneic hematopoietic stem cell transplantation (HSCT) to
prevent high-dose melphalan-induced stomatitis based on the hy-
pothesis that reduced peak drug level on oral mucosa by cryother-
apy could ameliorate mucosal injury. Eleven patients conditioned
by high-dose melphalan (70mg/m2 2) in combination with ﬂu-
darabine (25mg/m2 5; n  9), ﬂudarabineTBI (4Gy; n  1),
and ﬂudarabinehigh-dose cytarabine (3g/m24; n  1) were
evaluable. Stem cell sources were as follows: related bone marrow,
5; unrelated bone marrow, 4; unrelated cord blood, 2. Cyclosporin
A sMTX (n 4), tacrolimus sMTX (n 5), and cyclosporine
alone (n  2) were used for acute GVHD prophylaxis. Patients
received oral cyotherapy with ice chips and iced water for 15
minutes before and during the administration of melphalan, and
for further 60-90 minutes after the completion of melphalan ad-
ministration. For toxicity grading of stomatitis, NCI common
toxicity criteria was used. Eight patients receiving high-dose mel-
phalan (70mg/m22) in combination with ﬂudarabine for alloge-
neic HSCT without oral cyotherapy were used as a comparable
historical control. The grades of stomatitis were 0 (none) or 1 in all
11 patients receiving oral cryotherapy, while grades of stomatitis
were 0 or 1 in 1 patient, and 2 or 3 in 7 of 8 patients in the control
group (P  0.05). We conclude that oral cryotherapy prevents
stomatitis induced by high-dose melphalan, and recommend that it
be incorporated into the conditioning regimen consisting of high-
dose melphalan.
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CLINICAL EFFICACY OF GRANULOCYTE TRANSFUSION IN PATIENTS
WITH SEVERE NEUTROPENIC INFECTIONS
Kim, J.-S., Kim, S.I., Park, S.-R., Baek, J.Y., Choi, I.S., Yoon, S.-S.,
Lee, J.S., Park, S., Kim, B.K. Seoul National University Hospital,
Seoul, Republic of Korea
Granulocyte transfusions have been advocated for the treatment
of severe, progressive infections in neutropenic patients who fail to
respond to antimicrobial agents and recombinant hematopoietic
growth factors. We conducted the current study to evaluate the
safety and efﬁcacy of granulocyte transfusion therapy in patients
with neutropenia-related infections. To mobilize granulocytes,
healthy normal donors were stimulated with G-CSF 300ug SC
dexamethasone 8mg po prior to leukapheresis. Before granulocyte
transfusion, recipients were given hydrocortisone and phenira-
mine. Twenty-nine patients with severe neutropenia-related infec-
tions unresponsive to appropriate antimicrobial agents received a
total of 36 sessions of granulocyte transfusions (total transfusion
number  148). Among these, 17 sessions were done with preir-
radiated leukapheresis products. 22 of 36 sessions (61.1%) re-
sponded with resolution of neutropenic fever, and side effects,
mostly urticaria, were noticed in 13 sessions (36.1%), including 3
cases of peri-transfusion mortality. ANC increment(1495 vs 526),
mean duration of antibiotic use (20.8 vs 34.3) and neutropenia
(24.0 vs 35.9) were signiﬁcantly different between responders and
non-responders (p 0.042, 0.058 and 0.043 respectively). Number
of transfusion, granulocyte dose, age and irradiation were not
signiﬁcantly different between the 2 groups. We conclude that
granulocyte transfusion therapy was useful and safe when the
severity of infection and the host’s immunodeﬁciency make any
other antimicrobial treatment ineffectual.
Table. Treatment Outcome
Responder Non-responder P Value
No. of session 22 (61.1%) 14 (38.9%)
Mean prior
duration of
Antibiotics 20.8  12.4 34.4  26.1 P  0.043
Neutropenia 24.0  12.4 35.9  24.2 P  0.058
G-CSF 11.6  7.9 18.5  12.9 n.s.
Irradiation (/) 12/10 5/9 n.s.
No. of transfusion
(mean) 3.8  1.4 4.6  6.3 n.s.
ANC increment
(mean) 1495  1564 526  646 P  0.042
Granulocyte dose
(1010 cell/kg) 5.4  1.6 6.0  2.9 n.s.
n.s., not signiﬁcant.
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